Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PDE6D | O43924 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799327 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2050594 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2050597 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1978780 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL8239672 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL7933980 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL9611179 | 0.94 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3259413 | 0.92 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13100382 | 0.92 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13637135 | 0.92 | HMGCR (0.46) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111100075-B | Method for preparing rosuvastatin and pitavastatin 2, 6-diene heptanoate compound | 南通常佑药业科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-111100075-A | Method for preparing rosuvastatin and pitavastatin 2, 5-diene heptanoate compound | 南通常佑药业科技有限公司 | 2020-05-05 | — | — | CN | claimed |
| EP-2373609-B1 | USE OF AMPHIPHILIC COMPOUNDS FOR CONTROLLED CRYSTALLIZATION OF STATINS AND STATIN INTERMEDIATES | KRKA D D NOVO MESTO (SI) | 2013-10-16 | — | — | EP | claimed |
| WO-2011083495-A2 | PROCESS FOR THE PREPARATION OF DIHYDROXY PROTECTED DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | MSN LABORATORIES LIMITED (IN) | 2011-07-14 | — | — | WO | claimed |
| EP-2327682-A1 | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates | KRKA, D.D., Novo Mesto (SI) | 2011-06-01 | — | — | EP | claimed |
| WO-2009157014-A2 | A PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2009-12-30 | — | — | WO | claimed |
| WO-2019008593-A1 | PROCESS FOR MANUFACTURE OF ROSUVASTATIN CALCIUM AMORPHOUS | Melody Healthcare Pvt. Ltd (IN) | 2019-01-10 | — | — | WO | disclosed |
| US-9926283-B2 | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9926283-B2 | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9850213-B2 | Method for preparing rosuvastatin sodium | JIANGXI BOYA SEEHOT PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| EP-3115367-B1 | INTERMEDIATE COMPOUND FOR PREPARING ROSUVASTATIN CALCIUM AND METHOD FOR PREPARING ROSUVASTATIN CALCIUM THEREFROM | ASYMCHEM LABORATORIES (TIANJIN) CO LTD (CN) | 2017-11-01 | — | — | EP | disclosed |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | FUDAN UNIVERSITY (CN) | 2017-06-29 | — | — | US | disclosed |
| US-20170022169-A1 | INTERMEDIATE COMPOUND FOR PREPARING ROSUVASTATIN CALCIUM AND METHOD FOR PREPARING ROSUVASTATIN CALCIUM THEREFROM | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2017-01-26 | — | — | US | disclosed |
| WO-2007125547-A2 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SATYANARAYANA REDDY MANNE (IN) | 2007-11-08 | — | — | WO | disclosed |
| US-20070255060-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | ASTRAZENECA UK LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| WO-2007099561-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | CADILA HEALTHCARE LIMITED (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-20070155765-A1 | Method of preparation of the hemi-calcium salt of (e)-7-[4-(4fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonvl)aminolpyrimidin-5-yl](3r,5s)-3,5-, dihvdroxy-6-heptenoic acid | ZENTIVA, A.S. (CZ) | 2007-07-05 | — | — | US | disclosed |
| US-20070155765-A1 | Method of preparation of the hemi-calcium salt of (e)-7-[4-(4fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonvl)aminolpyrimidin-5-yl](3r,5s)-3,5-, dihvdroxy-6-heptenoic acid | ZENTIVA, A.S. (CZ) | 2007-07-05 | — | — | US | disclosed |
| EP-1704144-B1 | A METHOD OF PREPARATION OF THE HEMI-CALCIUM SALT OF (E)-7- [4-(4-FLUOROPHENYL)-6-ISOPROPYL-2- [ME THYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXY-6-HEPTENOIC ACID | ZENTIVA AS (CZ) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022169-A1 | INTERMEDIATE COMPOUND FOR PREPARING ROSUVASTATIN CALCIUM AND METHOD FOR PREPARING ROSUVASTATIN CALCIUM THEREFROM | HMGCR, REN, PCSK9 | HMGCR 1/4885ALDH1A1 3405/4885CYP3A4 812/4885 |
| US-20070255060-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | HMGCR, DHCR7, FADS2 | HMGCR 1/4885ALDH1A1 1920/4885CYP3A4 1172/4885 |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | HMGCR, NOX4, PTEN | HMGCR 1/4885ALDH1A1 1238/4885CYP3A4 94/4885 |
| US-20070155765-A1 | Method of preparation of the hemi-calcium salt of (e)-7-[4-(4fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonvl)aminolpyrimidin-5-yl](3r,5s)-3,5-, dihvdroxy-6-heptenoic acid | HRH4, HRH3, CACNA1E | HMGCR 7/4885ALDH1A1 4024/4885CYP3A4 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.